Skip to content

The use of dexmedetomidine in general anesthesia in obstetric patients:clinical observation and animal experiment

The use of dexmedetomidine in general anesthesia in obstetric patients:clinical observation and animal experiment

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070965
Enrollment
Unknown
Registered
2023-04-27
Start date
2023-04-28
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstetrical anesthesia

Interventions

Control Group:Pump normal saline
DEX1 Group:Pump the first agent 0.4 µg/kg of DEX in 5 minutes followed by 0.4 µg/kg-1. h-1 continuous pumping
DEX2 Group:Pump the first agent 0.6 µg/kg of DEX in 5 minutes followed by 0.6 µg/kg-1. h-1 continuous pumping

Sponsors

Tianjin Center Obstetrics and Gynecology Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Full term pregnancy, singleton, ASA grade II, patients with intraspinal anesthesia contraindicated, or refused to implement intraspinal anesthesia.

Exclusion criteria

Exclusion criteria: Fetal distress or abnormal fetal heart rate, maternal bradycardia, DEX or sufentanil allergy.

Design outcomes

Primary

MeasureTime frame
Maternal plasma Adrenocorticotropic hormone;Maternal plasma Epinephrine;Maternal plasma Norepinephrine;Maternal plasma Eendorphin;Concentration of DEX in Maternal plasma ;Concentration of DEX in fetal plasma;

Secondary

MeasureTime frame
Maternal blood pressure;Maternal heart rate;Fetal heart rate;

Countries

China

Contacts

Public ContactZhiqiang Yu

Tianjin Center Obstetrics and Gynecology Hospital

120yuzhi@163.com+86 13820761323

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026